Article Text

Download PDFPDF
Upper airway.4: Sarcoidosis of the upper respiratory tract (SURT)
  1. Robert P Baughman1,
  2. Elyse E Lower2,
  3. Thomas Tami3
  1. 1University of Cincinnati Medical Center, Cincinnati, Ohio, USA
  2. 2Oncology Hematolgy Care, Cincinnati, Ohio, USA
  3. 3Cincinnati Sinus Institute, Cincinnati, Ohio, USA
  1. Correspondence to Professor Robert P Baughman, 1001 Holmes, Eden Ave, Cincinnati, OH 45267-0565, USA; bob.baughman{at}uc.edu

Abstract

Sarcoidosis of the upper respiratory tract (SURT) includes nasopharyngeal, laryngeal and tracheal disease. Documented SURT occurs in ∼5% of patients, although upper airway symptoms are more common in patients with sarcoidosis. Wegener granulomatosis may have a similar appearance to SURT, but there are important differences in the manifestations of the disease locally as well as systemically. In some cases, topical treatment is adequate to control SURT. However, many patients with significant sinus or laryngeal disease require long-term systemic treatment. While corticosteroids are often the initial drug of choice, there have been several reports of the effectiveness of cytotoxic agents and anti-tumour necrosis factor antibodies.

  • Sarcoidosis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Linked articles 112862, 112870, 112888, 125047.

  • Competing interests None.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles